Claims
- 1. An enantiomerically pure .beta.-D-dioxolanyl nucleoside of the structure: ##STR4## wherein R is OH, and X is selected from the group consisting of hydrogen, monophosphate, diphosphate, and triphosphate, or its pharmaceutically acceptable salt, and wherein the compound is at least 97% free of the corresponding .beta.-L-enantiomer.
- 2. An enantiomerically pure .beta.-D-dioxolanyl nucleoside of the structure: ##STR5## wherein R is NH.sub.2, and X is selected from the group consisting of hydrogen, monophosphate, diphosphate, and triphosphate, or its pharmaceutically acceptable salt, and wherein the compound is at least 97% free of the corresponding .beta.-L-enantiomer.
- 3. An enantiomerically pure .beta.-D-dioxolanyl nucleoside of the structure: ##STR6## wherein R is H or Cl, and X is selected from the group consisting of hydrogen, monophosphate, diphosphate, and triphosphate, or a pharmaceutically acceptable salt thereof, and wherein the compound is at least 97% free of the corresponding .beta.-L-enantiomer.
- 4. The compound of claim 1, wherein X is hydrogen.
- 5. The compound of claim 2, wherein X is hydrogen.
- 6. The compound of claim 3, wherein X is hydrogen.
- 7. (-)-(2R,4R)-9-�(-2-hydroxymethyl)-1,3-dioxolan-4-yl!guanine, which is at least 97% free of the corresponding .beta.-L-enantiomer.
- 8. (-)-(2R,4R)-2-amino-9-�(2-hydroxymethyl)-1,3-dioxolan-4-yl!adenine, which is at least 97% free of the corresponding .beta.-L-enantiomer.
- 9. (-)-(2R,4R)-2-amino-9-�(-2-hydroxymethyl)-1,3-dioxolan-4-yl!purine, which is at least 97% free of the corresponding .beta.-L-enantiomer.
- 10. (-)-(2R,4R)-2-amino-6-chloro-9-�(2-hydroxymethyl)- 1,3-dioxolan-4-yl!purine, which is at least 97% free of the corresponding .beta.-L-enantiomer.
- 11. The compound of claim 1, wherein X is monophosphate.
- 12. The compound of claim 2, wherein X is monophosphate.
- 13. The compound of claim 3, wherein X is monophosphate.
Parent Case Info
This application is a divisional application of U.S. Ser. No. 07/935,515 filed on Aug. 25, 1992, which is a continuation-in-part of U.S. Ser. No. 07/622,762 filed on Dec. 5, 1990, now U.S. Pat. No. 5,179,104.
Government Interests
The government has rights in this invention by virtue of grants from the Public Health Service of the National Institute of Allergy and Infectious Diseases, and the Department of Veterans Affairs that partially funded research leading to this invention.
US Referenced Citations (22)
Foreign Referenced Citations (1)
Number |
Date |
Country |
0 206 497 |
Dec 1986 |
EPX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
935515 |
Aug 1992 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
622762 |
Dec 1990 |
|